We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-5.97%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$522M
AUM Growth
-$108M
Cap. Flow
-$65.4M
Cap. Flow %
-12.54%
Top 10 Hldgs %
27.83%
Holding
119
New
12
Increased
37
Reduced
37
Closed
11

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$19.3M
2
MDT icon
Medtronic
MDT
+$16.9M
3
PFE icon
Pfizer
PFE
+$10.7M
4
ELV icon
Elevance Health
ELV
+$7.8M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$6.07M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$26.6M
2
CELG
Celgene Corp
CELG
+$10.4M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$8.57M
4
UNH icon
UnitedHealth
UNH
+$8.21M
5
MRK icon
Merck
MRK
+$7.97M

Sector Composition

Rank Sector Weight
1 Healthcare 94.79%
2 Financials 1.61%
3 Technology 0.16%
4 Energy 0.11%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DVAX
76
DELISTED
Dynavax Technologies
DVAX
$1.92M 0.37%
485,000
+185,000
+62% +$1.36M
CMRX
77
DELISTED
Chimerix, Inc.
CMRX
$1.84M 0.35%
400,000
-150,000
-27% -$708K
HALO icon
78
Halozyme
HALO
$12.2B
$1.78M 0.34%
180,000
-70,000
-28% -$767K
NBIX icon
79
Neurocrine Biosciences
NBIX
$16.6B
$1.55M 0.3%
40,000
– –
AERI
80
DELISTED
Aerie Pharmaceuticals
AERI
$1.32M 0.25%
+35,000
New +$1.32M
PODD icon
81
Insulet
PODD
$9.79B
$1.32M 0.25%
35,000
-22,000
-39% -$820K
TTPH
82
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$1.21M 0.23%
15,000
– –
RGLS
83
DELISTED
Regulus Therapeutics
RGLS
$1.05M 0.2%
3,901
+1,401
+56% +$455K
BDX icon
84
Becton Dickinson
BDX
$48.2B
$828K 0.16%
+5,125
New +$851K
ACHN
85
DELISTED
Achillion Pharmaceuticals
ACHN
$686K 0.13%
166,000
-100,000
-38% -$532K
MD icon
86
Pediatrix Medical
MD
$2.2B
$600K 0.12%
9,000
– –
TNDM icon
87
Tandem Diabetes Care
TNDM
$1.56B
$503K 0.1%
23,400
– –
ADVM
88
DELISTED
Adverum Biotechnologies
ADVM
$447K 0.09%
15,401
– –
VTRS icon
89
Viatris
VTRS
$18.9B
$382K 0.07%
+10,000
New +$372K
ATXS
90
DELISTED
Astria Therapeutics
ATXS
$361K 0.07%
1,667
– –
JPM icon
91
JPMorgan Chase
JPM
$950B
$353K 0.07%
4,087
+1,399
+52% +$107K
WFC icon
92
Wells Fargo
WFC
$264B
$337K 0.06%
6,118
+1,596
+35% +$80.3K
OCUL icon
93
Ocular Therapeutix
OCUL
$2.02B
$335K 0.06%
40,000
– –
STAA icon
94
STAAR Surgical
STAA
$1.21B
$312K 0.06%
+28,711
New +$292K
CNCE
95
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$310K 0.06%
30,099
– –
MSFT icon
96
Microsoft
MSFT
$3.71T
$298K 0.06%
4,793
+1,653
+53% +$99.4K
IBM icon
97
IBM
IBM
$224B
$293K 0.06%
1,847
+651
+54% +$99.2K
XOM icon
98
ExxonMobil
XOM
$634B
$288K 0.06%
3,195
+1,093
+52% +$95.5K
F icon
99
Ford
F
$55.7B
$273K 0.05%
22,511
+7,900
+54% +$95.8K
QCOM icon
100
Qualcomm
QCOM
$176B
$269K 0.05%
4,126
+1,257
+44% +$84.4K
1 2 3
4
5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2016 Portfolio in Review

As of Q4 2016, Rhenman & Partners Asset Management held 119 positions worth $522M, down 17% from $630M the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $65.4M in Q4 2016, closing 11 positions and reducing 37 holdings. Its most notable exit was Shire pic, an estimated $26.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 86% a quarter earlier, followed by Financials and Technology.

Against the trend, Rhenman & Partners Asset Management opened a new position in Gilead Sciences worth $18.6M.

  • Rhenman & Partners Asset Management's largest Q4 2016 buy was Gilead Sciences: 259,894 shares worth $18.6M.
  • Rhenman & Partners Asset Management added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2016, an estimated $6.07M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2016 reduction was Celgene Corp, cutting an estimated $10.4M.
  • Rhenman & Partners Asset Management fully exited Shire pic in Q4 2016, selling an estimated $26.6M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 28% of its $522M portfolio in Q4 2016.
  • Rhenman & Partners Asset Management opened 12 new positions and closed 11 in Q4 2016.
  • Rhenman & Partners Asset Management's portfolio value fell 17% quarter-over-quarter to $522M.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2016, filed 13 Jan 2017.